

# Product Pipeline

|                                                                                      | Phase I                                                 | Phase II | Phase III | Registration | Approval |
|--------------------------------------------------------------------------------------|---------------------------------------------------------|----------|-----------|--------------|----------|
| <b><u>Neratinib: Tyrosine kinase inhibitor</u></b>                                   |                                                         |          |           |              |          |
| <b>HER2+ Breast Cancer</b>                                                           | <b>ExteNET (Phase III HER2+ EBC*)</b>                   |          |           |              |          |
| <b>Extended adjuvant</b><br><i>Neratinib monotherapy</i>                             | <b>CONTROL</b>                                          |          |           |              |          |
| <b>Metastatic</b><br><i>Monotherapy or combo therapy</i>                             | <b>NALA (Phase III 3<sup>rd</sup> Line HER2+ MBC**)</b> |          |           |              |          |
| <b>Metastatic HER2 amplified/mutated</b><br><i>Combo with trastuzumab deruxtecan</i> | <b>NCT05372614</b>                                      |          |           |              |          |
| <b><u>Alisertib: Aurora kinase A inhibitor</u></b>                                   |                                                         |          |           |              |          |
| <b>HRc+*** HER2-negative MBC</b>                                                     | <b>ALISCA<sup>®</sup>-Breast1 (alisertib+endocrine)</b> |          |           |              |          |
| <b>Small cell lung cancer</b>                                                        | <b>ALISCA<sup>®</sup>-Lung1 (PUMA-ALI-4201)</b>         |          |           |              |          |

\*

\*